

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.

**The assessment of dietary iron bioavailability  
using the piglet as an animal model for the  
human infant**

A thesis presented in partial fulfilment of the requirements for  
the degree of Master of Science in Nutritional Science at Massey  
University, Palmerston North, New Zealand

**Caroline Elizabeth Gray**  
**1998**

## ABSTRACT

The bioavailability of five different iron sources added to a bovine milk based formula was investigated in the anaemic, suckled piglet. These iron sources were ferrous pyrophosphate (FP), ferrous sulphate (FS), milk protein-iron complex (MPIC), ferrous lactate (FL), and haemin (Hm). Forty eight male piglets were removed from the sow at five days of age and randomly assigned to one of six treatment groups (n=8). Iron depletion was achieved in two ways: firstly, by withholding the iron injection usually given to these piglets at birth, and secondly, by feeding the piglets an iron-deficient formula throughout an eleven day adjustment/iron-depletion period. The five formulas containing the supplementary iron and one formula containing no iron (control diet) were bottle-fed to the piglets (336g of liquid formula/kg bodyweight/day) seven times daily for a 25 day repletion period. Analysis of the formulas revealed that iron levels in each of the five iron treated formulas varied over a range of 6.0-8.3 mg/100g of powdered formula.

Iron bioavailability was assessed in the piglets by a haemoglobin repletion assay. Blood was collected from the anterior vena cava of the piglets on days 0, 11, 24, and 36 of the trial, and the piglets were weighed every three to four days throughout the 25 day repletion period. Blood haemoglobin concentration, haematocrit, unsaturated iron binding capacity, and piglet liveweights were used as indicators of iron status in the piglets. Haemoglobin Repletion Efficiency (HRE%), a measure of the proportion of ingested iron that is incorporated into haemoglobin in the body, was calculated to correct for differences in the iron content of the formula and differences in iron intake by the piglets. The HRE% for the FP, FS, MPIC, FL, and Hm fortified formulas were 23.5, 35.8, 38.0, 32.9, and 3.2%, respectively. There were no significant differences, however, in the mean blood haemoglobin concentrations, haematocrits, HRE% and UIBC for piglets fed the FS, MPIC, or the FL fortified formulas half way through, and at the end, of the repletion. This implied that there were no differences in the bioavailability of these iron sources. In contrast, these parameters were all significantly lower ( $P>0.05$ ), for the piglets

fed either the FP or the Hm formulas. Based on relative biological value, the bioavailability of each iron source, when ranked in order from highest to lowest, was  $MPIC < FS < FL < FP < Hm$ . These findings have important implications for the development of iron-enriched milk products destined for human consumption.

## ACKNOWLEDGEMENTS

Sincere gratitude belongs to my supervisors, Dr Alison J Darragh, and Dr Clare R Wall, for the commitment, encouragement and valuable criticism throughout the study. I thank Dr Linda M Schollum for her invaluable guidance and support in all aspects of the study.

Thanks is also due to Miss Nicki Frearson, Miss Geetha Kandia, Mrs Jiai Chen, Mr Gareth Dunkerly, Mr Daniel Johnson, Ms Suzanne Hodgkinson, Miss Lisel Trezise, Ms Sarah Blackburn, Miss Kim Kennedy, Miss Sarah Harris, Miss Sarah Eckhoff, Miss Reidun Baker, and Mr Barry Parlane for their indispensable assistance in the trial work; Dr Barbara Kuhn-Sherlock and Mr Robert Crawford for their work on statistical aspects of the study; and Dr Barbara Frey and Dr Mark Stevenson for their veterinary advice.

I would like to extend my appreciation to the people of the Milk and Health Research Centre and the Department of Animal Science at Massey University for their support. I gratefully acknowledge the financial assistance of the Milk and Health Research Centre.

Finally, I am indebted to my parents for their love, support, understanding, and belief in me.

## TABLE OF CONTENTS

	PAGE
Abstract	i
Acknowledgments	ii
List of Tables	iii
List of Figures	iv
<b>GENERAL INTRODUCTION</b>	1
<b><u>Chapter 1</u> REVIEW OF LITERATURE</b>	3
<b>1.1 Iron nutrition and metabolism in mammals</b>	3
1.1.1 Iron absorption and availability	6
1.1.1.1 Mechanisms of intestinal cell iron uptake	6
1.1.2 Iron transport and storage	11
1.1.3 Disorders of iron nutrition and metabolism	11
<b>1.2 Supplementation of iron in the diet</b>	13
<b>1.3 Methods used to investigate iron metabolism in humans</b>	15
1.3.1 In vitro measures of bioavailability	15
1.3.2 In vivo measures of bioavailability	16
1.3.2.1 Haemoglobin repletion	16
1.3.2.2 Isotopic methods	16
1.3.2.3 Other Parameters of iron status	18
1.3.3 The need for an animal model	18
1.3.4 Animal models used to study iron bioavailability	19

<b>1.4 Overall conclusion and inferences from the review of literature</b>	<b>28</b>
 <b><u>Chapter 2</u> MATERIALS AND METHODS</b>	<b>29</b>
<b>2.1 Animals and housing</b>	<b>29</b>
<b>2.2 Formulas and feeding</b>	<b>29</b>
<b>2.3 Experimental procedure</b>	<b>31</b>
<b>2.4 Chemical analysis</b>	<b>33</b>
2.4.1 Haemoglobin determination	33
2.4.2 Haematocrit	34
2.4.3 Unsaturated iron-binding capacity	34
2.4.4 Protein determination	35
2.4.5 Energy determination	35
2.4.6 Iron determination	36
<b>2.5 Data analysis</b>	<b>36</b>
 <b><u>Chapter 3</u> RESULTS</b>	<b>38</b>
<b>2.1 Piglet growth and feeding</b>	<b>38</b>
<b>2.2 Effects of iron treatment across time</b>	<b>42</b>
<b>2.3 Comparative effect of different iron source</b>	<b>44</b>
 <b><u>Chapter 4</u> DISCUSSION</b>	<b>50</b>
 <b><u>Chapter 5</u> GENERAL DISCUSSION AND SUMMARY</b>	<b>59</b>
 <b>REFERENCE LIST</b>	<b>67</b>
 <b>APPENDICES</b>	<b>77</b>

## LIST OF TABLES

Table	Page
1.1 Major iron-containing and iron binding proteins and their functions.	4
1.2 The development of iron deficiency anaemia.	12
1.3 Concentration and distribution of iron in milk of various species.	21
1.4 Logistical advantages to using the pig as a model for human nutrition.	27
2.1 Ingredient composition of six bovine milk-based formulas with or without iron supplementation.	38
2.2 Nutrient composition of six bovine milk-based formulas with or with iron supplementation.	31
3.1 Initial liveweights of piglets, assigned to either a control diet containing no iron or one of five bovine milk-based.	39
3.2 Average Formula Intakes (mean ml/feed/day $\pm$ SE) in piglets fed bovine milk-based formulas fortified with different sources of iron over a 25 day experimental period.	41
3.3 Haemoglobin concentration (mean $\pm$ SE; g/dL) and Haematocrit (mean $\pm$ SE; %) in the blood collected from piglets fed a bovine milk-based follow-on infant formula, (containing no additional iron), for a 13 day experimental period.	42

- 3.4 Haemoglobin levels (mean  $\pm$  SE; g/dL) in blood collected from piglets immediately after being removed from the sow and during a 25 day repletion period where the piglets were fed a bovine milk-based formula fortified with one of five different sources of iron. 46
- 3.5 Haematocrit levels (mean  $\pm$  SE, PCV %) in blood collected from piglets immediately after being removed from the sow and during a 25 day repletion period when the piglets were fed a bovine milk-based formula fortified with one of five sources of iron. 47
- 3.6 Unsaturated iron-binding capacity (mean UIBC  $\pm$  SE;  $\mu$ g/dL) in blood collected from piglets during a 25 day repletion period when the piglets were fed a bovine milk-based formula fortified with one of five different sources of iron. 48
- 3.7 Haemoglobin repletion efficiency (%) (mean HRE  $\pm$  SE) of different iron sources used to fortify a bovine milk-based formula as determined in anaemic piglets over a 25 day haemoglobin repletion period. 49
- 4.1 The relative biological value (RBV) of five different iron sources used to fortify a bovine-milk based formula. 54
- 5.1 The normal range for blood haemoglobin concentration and haematocrit in the three-week-old piglet and the three-month-old human infant. 65

## LIST OF FIGURES

Figure	Page
1.1 Enterocyte uptake and transfer of iron	7
3.1 Average ( $\pm$ SE) daily weight gains (kg/d ) for three time periods (days 0-10, 11-24 and 25-36 of the trial) in piglets fed one of five iron fortified bovine milk-based formulas (Control, FS = Ferrous sulphate heptahydrate, MPIC = Milk protein-iron complex, FL = Ferrous lactate, and Hm = Haemin) over treatment period of 25 days.	48
3.2 Boxplots representing the range, mean and upper and lower quartiles for the haemoglobin repletion efficiencies (HRE%) of five groups of piglets fed a bovine milk-based formula fortified with different sources of iron (FS = Ferrous sulphate heptahydrate, MPIC = Milk protein-iron complex, FL = Ferrous lactate, and Hm = Haemin).	45

## GENERAL INTRODUCTION

Today, iron deficiency is one of the most prevalent nutritional deficiencies among infants and young children in both industrialised and developing countries (Kuvibidila *et al.*, 1984; FAO/WHO, 1988; Zeigler and Fomon, 1996; Looker *et al.*, 1997). The effects of iron deficiency on erythropoiesis, work capacity, cognitive performance (Pollitt, 1997), behaviour (Andraca *et al.*, 1997), and more recently cell mediated immunity (Kuvibidila *et al.*, 1984; Walter *et al.*, 1997) are well documented. These effects highlight the need for early detection and treatment of iron deficiency and its associated anaemia during this age of increased risk.

Infants and young children have an increased risk of deficiency because of the demands imposed in times of increased growth. The growth of the body necessitates an increase in the total volume of blood to keep pace with its size. Moreover, there is a steady increase in the haemoglobin content per unit blood volume from age six months. A greater demand for iron comes also, from the expanding muscle mass during growth. At birth, the full-term human infant is endowed with iron stores sufficient to satisfy the body's demand for iron for the first four to six months of life. The infant can be fed a low iron diet during this time without demonstrating overt signs of iron deficiency. After the first four to six months, however, the depletion of iron stores that results from increased growth rates and a diet low in iron, introduces a high risk of iron deficiency to the infant. While the high bioavailability of breast milk iron confers a partial protection against deficiency, the quantity of iron absorbed from an unsupplemented diet, from about four months of age onwards, is no longer sufficient to meet the needs of infants (Saarinen, 1978; Dallman *et al.*, 1980).

The fortification of foods with iron offers a suitable means of prevention and treatment of iron deficiency and its associated anaemia. Infant formula provides an appropriate vehicle for iron fortification for infants who are not breast-fed because it is consumed by these infants in large quantities. Iron fortification of infant formulas and cereals was introduced in the 1960's (Zeigler and Fomon,

1996). Today, the level of fortification of infant formula typically ranges from 8-12mg/L, primarily in the form ferrous sulphate or ferrous lactate. The iron sources of choice are those with acceptably high bioavailability. The absorption of dietary iron depends on the bioavailability of the iron which is, in turn, affected by various dietary factors. It is, therefore, important to get reliable estimates of the bioavailability of different iron sources under appropriate conditions.

The objective of this study was to test the bioavailability, to the human infant, of iron from different sources. Central to this objective was the use of a suitable animal model for infant iron nutrition.